CryoLife First Quarter 2004 Revenues Up 18% Over Fourth Quarter 2003
May 10 2004 - 9:56AM
PR Newswire (US)
CryoLife First Quarter 2004 Revenues Up 18% Over Fourth Quarter
2003 Continued Strong Growth of U.S. and International BioGlue(R)
Sales ATLANTA, May 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. , a
bio-surgical device and human tissue processing company, today
reported financial results for the first quarter of 2004. Revenues
for the first quarter of 2004 were $15.1 million, an increase of
18% compared to the fourth quarter of 2003. Revenues for the first
quarter of 2003 were $15.9 million. Net loss for the first quarter
of 2004 was $7.0 million compared to a net loss of $7.2 million in
the fourth quarter of 2003 and a net loss of $434,000 in the first
quarter of 2003. On a fully diluted basis, the loss per common
share for the first quarter of 2004 was $0.32 compared to a net
loss per share of $0.37 in the fourth quarter of 2003 and a net
loss per share of $0.02 in the first quarter of 2003. BioGlue sales
in the first quarter of 2004 increased 11% to $8.6 million compared
to $7.8 million in the fourth quarter of 2003 and increased 33%
compared to $6.5 million in the first quarter of 2003. BioGlue
revenues are expected to increase by 19-26% to between $33 and $35
million in 2004 from $27.8 million in 2003. Projected BioGlue
revenue for the second quarter is $8.5-$9.0 million. BioGlue can be
distributed in 50 countries. Surgeons in the U.S. are utilizing it
as an adjunct to standard methods, such as sutures and staples, to
control bleeding in open surgical repair of large vessels. It is
being used in the European community in the surgical repair of soft
tissues, such as vascular, cardiac, lung, and gastrointestinal as
well as dura sealing for use in brain and spinal surgery.
"International BioGlue sales growth of 24% in the first quarter of
2004 compared to the first quarter of 2003 was driven by the U.K.
direct sales representatives, strong distribution support
throughout Europe, increased usage of BioGlue in the core
applications of cardiac and large vascular surgery, and expanded
usage in neurologic, pulmonary, and general surgery," said Steven
G. Anderson, President and CEO. "Recently, there have been several
presentations and publications, both in the U.S. and abroad,
describing the use of BioGlue for various surgical indications.
This positive data has been an important factor driving BioGlue
sales growth," said Mr. Anderson. Tissue processing revenues
including cardiac, vascular, and orthopaedic tissue, increased 26%
to $6.2 million in the first quarter of 2004 compared to $4.9
million in the fourth quarter of 2003. Total tissue processing
revenues are expected to increase by 4-10% to between $32 and $34
million in 2004 from $30.8 million in 2003. Projected tissue
processing revenue for the second quarter is $6.7-$7.5 million.
Cardiac tissue processing revenues were $3.4 million in the first
quarter of 2004, compared to $2.8 million in the fourth quarter of
2003. Vascular tissue processing revenues were $2.5 million in the
first quarter of 2004 compared to $2.0 million in the fourth
quarter of 2003. Orthopaedic revenues were $309,000 in the first
quarter of 2004 compared to $166,000 in the fourth quarter of 2003.
Total tissue processing and product revenues are projected to be
between $15.3 and $16.6 million in the second quarter of 2004, up
from $15.1 million for the first quarter of 2004. Total tissue
processing and product revenues are expected to increase 12-19% to
$66-$70 million for the full year 2004. General, administrative,
and marketing expenses are expected to be approximately $42-$46
million in 2004, while research and development expenses are
expected to be approximately $4 million in 2004. For the second
quarter of 2004, the Company expects general, administrative, and
marketing expenses of approximately $10-$11 million, and expects
research and development expenses to be approximately $1 million.
Separately, the Company noted that in connection with its form S-3
filing, the Securities and Exchange Commission ("SEC") has
conducted a review of the Company's 10-K and 10-Q's. As a result of
this review, the Company is addressing with the SEC the accounting
treatment for its product liability cases. The Company believes
that the results of the review will not change its previously
reported operating results. The Company's Form 10-Q will be delayed
in order to allow the Company time to complete its communications
with the SEC regarding its review. Since the beginning of 2003 the
Company has settled approximately 30 product liability claims,
which has reduced the number of product liability cases pending
against the Company to 10, four of which are covered by insurance.
As of March 31, 2004, the Company had approximately $25.4 million
in aggregate cash, cash equivalents, and marketable securities.
Additionally, the Company expects to receive tax refunds of
approximately $2.4 million in the second half of 2004. The Company
will hold a teleconference call and live web cast today at 11:15
a.m. Eastern Time, to discuss first quarter 2004 results, followed
by a question and answer session hosted by Steven G. Anderson,
CryoLife President and Chief Executive Officer. To listen to the
live teleconference, please dial 973-935-8505 a few minutes prior
to 11:15 a.m. No identification number is required. A replay of the
teleconference will be available May 10 through May 14 and can be
accessed by calling (toll free) 877-519-4471 or 973-341-3080. The
identification number for the replay is 4701009. The live web cast
can be accessed by going to the Investor Relations section of the
CryoLife web site at http://www.cryolife.com/ . Founded in 1984,
CryoLife, Inc. is a leader in the processing and distribution of
implantable living human tissues for use in cardiovascular and
vascular surgeries throughout the United States and Canada. The
Company's BioGlue Surgical Adhesive is FDA approved as an adjunct
to sutures and staples for use in adult patients in open surgical
repair of large vessels and is CE marked in the European Community
and approved in Canada for use in soft tissue repair and approved
in Australia for use in vascular and pulmonary sealing and repair.
The Company also manufactures the SynerGraft Vascular Graft, which
is CE marked for distribution within the European Community.
Statements made in this press release that look forward in time or
that express management's beliefs, expectations or hopes are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These future events may
not occur as and when expected, if at all, and, together with the
Company's business, are subject to various risks and uncertainties.
These risks and uncertainties include that the Company's 2004
revenues and expenses may not meet its expectations, that the
Company's 2004 BioGlue revenues may not meet its expectations, that
the demand for CryoLife preserved tissues may not return to prior
levels, that the Company's 10-Q may be delayed, the possibility
that the FDA could impose additional restrictions on the Company's
operations, require a recall, or prevent the Company from
processing and distributing tissues or manufacturing and
distributing other products, that FDA regulations of the Company's
CryoValve SG and CryoVein SG may require significant time and
expense, that the protein hydrogel products under development may
not be commercially feasible, that the Company may not have
sufficient borrowing or other capital availability to fund its
business, that pending litigation cannot be settled on terms
acceptable to the Company, that the Company may not have sufficient
resources to pay punitive damages (which are not covered by
insurance) or other liabilities in excess of available insurance,
the possibility of severe decreases in the Company's revenues and
working capital, that to the extent the Company does not have
sufficient resources to pay the claims against it, it may be forced
to cease operations or seek protection under applicable bankruptcy
laws, changes in laws and regulations applicable to CryoLife and
other risk factors detailed in CryoLife's Securities and Exchange
Commission filings, including CryoLife's Form 10-K filing for the
year ended December 31, 2003, and the Company's other SEC filings.
The Company does not undertake to update its forward-looking
statements. For additional information about the company, visit
CryoLife's Web site: http://www.cryolife.com/ Contact: Joseph T.
Schepers Vice President, Corporate Communications (770) 419-3355
CRYOLIFE, INC. Unaudited Financial Highlights (In thousands, except
per share data) Three Months Ended March 31, 2004 2003 Revenues:
Human tissue preservation services $6,225 $ 9,130 Products 8,859
6,599 Grant 2 191 Total revenues 15,086 15,920 Costs and expenses:
Human tissue preservation services 9,103 2,443 Products 1,947 1,641
General, administrative, and marketing 10,148 11,592 Research and
development 921 917 Interest expense 43 132 Interest income (66)
(131) Other expense (income), net 16 (26) Total costs and expenses
22,112 16,568 Loss before income taxes (7,026) (648) Income tax
expense (benefit) -- (214) Net loss $(7,026) $(434) Loss per share:
Basic $(0.32) $(0.02) Diluted $(0.32) $(0.02) Weighted average
shares outstanding: Basic 22,241 19,634 Diluted 22,241 19,634
Revenues from: Cardiovascular $3,430 $4,725 Vascular 2,486 4,255
Orthopaedic 309 150 Total cryopreservation 6,225 9,130 BioGlue
8,643 6,494 Implantable medical devices 216 105 Grant 2 191 Total
revenues $15,086 $15,920 International revenues $2,092 $1,710
Domestic revenues 12,994 14,210 Total revenues $15,086 $15,920
DATASOURCE: CryoLife, Inc. CONTACT: Joseph T. Schepers, Vice
President, Corporate Communications of CryoLife, Inc.,
+1-770-419-3355 Web site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024